Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

It is becoming apparent that autoantibodies contribute to neuropathic pain in a range of neurological conditions. In some cases, these autoantibodies clearly evoke injury (e.g., GBS or transverse myelitis); in others, they appear to directly regulate excitability of the sensory nervous system. There are immunotherapies that can reduce autoantibody levels, and confirmation that these autoantibodies are causal to pain will improve analgesic treatment strategies for these patients. For example, in patients with VGKCC-Ab, the effectiveness of immunotherapy in reducing pain has lessened the need for opioid treatment, resulting in a reprieve from the harmful side effects of narcotics and better pain management (Gadoth et al., 2017). An improved understanding of the prevalence of autoantibodies is needed and may provide an explanation for certain idiopathic pain conditions. Moreover, the work on autoantibodies can be used as a tool to provide insight into clinically relevant mechanisms controlling pain sensitivity in the more general context and help steer the future development of therapies to treat neuropathic pain.



Book title

The Oxford Handbook of the Neurobiology of Pain

Publication Date



833 - 850